Lithium mupirocin
Modify Date: 2024-01-07 11:38:35
Lithium mupirocin structure
|
Common Name | Lithium mupirocin | ||
|---|---|---|---|---|
| CAS Number | 73346-79-9 | Molecular Weight | 506.56 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H43LiO9 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
Use of Lithium mupirocinMupirocin (BRL-4910A) lithium is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin lithium apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis[1][2][3][4][5]. |
| Name | lithium,9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate |
|---|---|
| Synonym | More Synonyms |
| Description | Mupirocin (BRL-4910A) lithium is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin lithium apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis[1][2][3][4][5]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C26H43LiO9 |
|---|---|
| Molecular Weight | 506.56 |
| Exact Mass | 500.29900 |
| PSA | 146.05000 |
| LogP | 2.59250 |
| RIDADR | NONH for all modes of transport |
|---|
|
Short-term decline in all-cause acquired infections with the routine use of a decontamination regimen combining topical polymyxin, tobramycin, and amphotericin B with mupirocin and chlorhexidine in the ICU: a single-center experience.
Crit. Care Med. 42(5) , 1121-30, (2014) In a multicenter, placebo-controlled, randomized, double-blind trial, we showed that acquired infections in intubated patients were reduced by the combination of topical polymyxin plus tobramycin and ... |
|
|
Oral antibiotics versus topical decolonization to prevent surgical site infection after Mohs micrographic surgery--a randomized, controlled trial.
Dermatol. Surg. 39(10) , 1486-93, (2013) The optimal method of reducing the risk of surgical site infection (SSI) after dermatologic surgery is unclear. Empiric, preoperative antibiotic use is common practice but lacks supporting evidence fo... |
|
|
Screening for MRSA and isolating carriers doesn't reduce ICU infections.
BMJ 346 , f3581, (2013)
|
| Lithium mupirocin |
| Li-MUP |
| Pseudomonic acid A lithium salt |
| 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid lithium salt |
| Lithium mupirocin Supplement |
| Lithium mupirocin solution |